- United States
- /
- Software
- /
- NasdaqGS:EXFY
Growth Companies With High Insider Ownership For April 2025
Reviewed by Simply Wall St
As the U.S. market grapples with the impact of newly announced tariffs, resulting in a sharp decline across major indices like the Dow Jones and Nasdaq, investors are increasingly focused on how these measures might affect economic growth and corporate profits. In such volatile conditions, companies with strong insider ownership often attract attention as they can indicate confidence from those who know the business best; this article highlights three growth companies in the United States where insiders hold significant stakes.
Top 10 Growth Companies With High Insider Ownership In The United States
Name | Insider Ownership | Earnings Growth |
Super Micro Computer (NasdaqGS:SMCI) | 14.2% | 29.8% |
Hims & Hers Health (NYSE:HIMS) | 13.2% | 21.8% |
Duolingo (NasdaqGS:DUOL) | 14.4% | 37.3% |
Coastal Financial (NasdaqGS:CCB) | 14.5% | 46.3% |
Astera Labs (NasdaqGS:ALAB) | 15.9% | 61.3% |
Clene (NasdaqCM:CLNN) | 19.5% | 63.1% |
FTC Solar (NasdaqCM:FTCI) | 31.6% | 62.2% |
BBB Foods (NYSE:TBBB) | 16.2% | 34.5% |
Upstart Holdings (NasdaqGS:UPST) | 12.7% | 100.1% |
Credit Acceptance (NasdaqGS:CACC) | 14.4% | 33.9% |
Below we spotlight a couple of our favorites from our exclusive screener.
Niagen Bioscience (NasdaqCM:NAGE)
Simply Wall St Growth Rating: ★★★★☆☆
Overview: Niagen Bioscience, Inc. is a bioscience company focused on developing healthy aging products, with a market cap of $535.29 million.
Operations: The company's revenue is primarily derived from Consumer Products at $76.77 million, followed by Ingredients at $19.81 million, and Analytical Reference Standards and Services at $3.01 million.
Insider Ownership: 29.8%
Niagen Bioscience, recently rebranded from ChromaDex Corporation, is positioned for significant growth with expected annual earnings increase of 32.2%, outpacing the US market. The company has a robust intellectual property portfolio with over 90 patents on NAD+ precursors and a new patent enhancing its competitive edge. Insider buying has occurred but not in substantial volumes. Despite high share price volatility, Niagen trades slightly below fair value and projects an 18% revenue growth for 2025.
- Delve into the full analysis future growth report here for a deeper understanding of Niagen Bioscience.
- Our comprehensive valuation report raises the possibility that Niagen Bioscience is priced higher than what may be justified by its financials.
Bowman Consulting Group (NasdaqGM:BWMN)
Simply Wall St Growth Rating: ★★★★☆☆
Overview: Bowman Consulting Group Ltd. offers engineering, technical, and technology-enhanced consulting services in the United States with a market cap of $378.25 million.
Operations: The company's revenue is primarily derived from providing engineering and related professional services, totaling $426.56 million.
Insider Ownership: 19.6%
Bowman Consulting Group is experiencing robust growth, with expected annual earnings increases of 57.3%, significantly outpacing the US market. Despite trading 59.2% below its estimated fair value, revenue growth forecasts at 9.3% remain modest relative to earnings potential. Recent contracts, including a $2.2 million ADA project in Philadelphia and $3.8 million water resource projects in Colorado, highlight Bowman's strategic expansion and ability to secure substantial infrastructure assignments without significant recent insider trading activity.
- Navigate through the intricacies of Bowman Consulting Group with our comprehensive analyst estimates report here.
- Our expertly prepared valuation report Bowman Consulting Group implies its share price may be lower than expected.
Expensify (NasdaqGS:EXFY)
Simply Wall St Growth Rating: ★★★★★☆
Overview: Expensify, Inc. provides a cloud-based expense management software platform operating both in the United States and internationally, with a market cap of approximately $269.67 million.
Operations: The company generates revenue primarily from its Internet Software & Services segment, amounting to $139.24 million.
Insider Ownership: 30%
Expensify is positioned for growth, with revenue expected to outpace the US market at 8.7% annually. Despite a net loss of US$10.06 million in 2024, losses have narrowed significantly from the previous year. The company has launched Expensify Travel, enhancing its platform's appeal and functionality. It trades at a substantial discount to estimated fair value and plans a US$50 million share repurchase program, indicating confidence in future prospects despite no recent insider trading activity.
- Click here to discover the nuances of Expensify with our detailed analytical future growth report.
- Our comprehensive valuation report raises the possibility that Expensify is priced lower than what may be justified by its financials.
Turning Ideas Into Actions
- Delve into our full catalog of 204 Fast Growing US Companies With High Insider Ownership here.
- Interested In Other Possibilities? Uncover the next big thing with financially sound penny stocks that balance risk and reward.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.
If you're looking to trade Expensify, open an account with the lowest-cost platform trusted by professionals, Interactive Brokers.
With clients in over 200 countries and territories, and access to 160 markets, IBKR lets you trade stocks, options, futures, forex, bonds and funds from a single integrated account.
Enjoy no hidden fees, no account minimums, and FX conversion rates as low as 0.03%, far better than what most brokers offer.
Sponsored ContentValuation is complex, but we're here to simplify it.
Discover if Expensify might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
About NasdaqGS:EXFY
Expensify
Engages in the provision of a cloud-based expense management software platform in the United States and internationally.
Flawless balance sheet with high growth potential.
Similar Companies
Market Insights
Community Narratives

